Dissemin is shutting down on January 1st, 2025

Published in

Springer Nature [academic journals on nature.com], British Journal of Cancer, 6(57), p. 579-586, 1988

DOI: 10.1038/bjc.1988.132

Links

Tools

Export citation

Search in Google Scholar

Bombesin and bombesin antagonists: Studies in Swiss 3T3 cells and human small cell lung cancer

Journal article published in 1988 by Woll Pj, Pj J. Woll ORCID, E. Rozengurt
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Bombesins are potent growth factors for murine Swiss 3T3 cells. Using these cells in chemically defined conditions we have been able to characterise the bombesin receptor and the early signals preceding DNA synthesis. We describe two substance P analogues [DArg1, DPro2, DTrp7,9, Leu11] substance P and [DArg1, DPhe5, DTrp7,9, Leu11] substance P which competitively block the binding of bombesins to their receptor and all the events leading to mitogenesis. Bombesins are secreted by human small cell lung cancers (SCLC) and may act as autocrine growth factors for these tumours, so the development of peptide bombesin antagonists could have therapeutic implications. We demonstrate that the antagonists can reversibly inhibit the growth of SCLC in vitro, with relatively little effect on other lung tumours.